Lazard Asset Management LLC Adaptimmune Therapeutics PLC Transaction History

Lazard Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.43 - $0.79 $82 - $152	-193 Reduced 4.43%	4,160 $3,000
Q3 2023 Nov 14, 2023	BUY	$0.73 - $1.04 $135 - $192	185 Added 4.44%	4,353 $3,000
Q2 2023 Aug 14, 2023	SELL	$0.9 - $1.51 $13,617 - $22,846	-15,130 Reduced 78.4%	4,168 $3,000
Q1 2023 May 15, 2023	SELL	$1.06 - $2.16 $84,049 - $171,270	-79,292 Reduced 80.43%	19,298 $20,000
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $103,519 - $249,432	98,590 New	98,590 $143,000
Q3 2018 Nov 13, 2018	SELL	$8.27 - $13.56 $1.33 Million - $2.18 Million	-160,892 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$10.42 - $13.74 $512,768 - $676,145	49,210 Added 44.06%	160,892 $1.91 Million
Q1 2018 May 14, 2018	BUY	$7.1 - $11.56 $792,942 - $1.29 Million	111,682 New	111,682 $1.25 Million

152M

78.5K

36.5K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $121M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.